TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03737396

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered electronic health screening
Description: Health assessment using an electronic device
Study: NCT03143894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation (tDCS)..

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation (tDCS)..
Study: NCT02353104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Onion-Pumpkin Extract
Study: NCT00808366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratolytic/Antifungal
Description: Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keratolytic/Antifungal
Description: Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Study: NCT02454998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
Study: NCT02067338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg morphine soak in epidural oxidized cellulose
Description: During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
Study: NCT00682162

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser acupuncture
Description: The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
Study: NCT01876797

Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor/prasugrel
Study: NCT01953263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Fiber Fragments
Description: Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
Study: NCT02039492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathetic Renal Denervation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with aldactone
Study: NCT01024634

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Exercise
Description: 8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Endurance Exercise
Description: 8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
Study: NCT04517812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based games via the VirtualRehab platform
Description: A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
Study: NCT03937011

Intervention type: DEVICE
Intervention: Robotic Suturing of gastric sleeve oversew and vaginal cuff closure
Description: 1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;
Study: NCT00694785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6
Study: NCT02270957

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Study: NCT02286752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
Study: NCT01638975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Inhibition Training Program
Description: This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
Study: NCT02270957

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00048555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDEC-114
Description: Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
Study: NCT03516994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respecting Choices First Steps
Description: Advance Care Planning Approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Five Wishes Form
Description: Advance Care Planning Approach
Study: NCT03752294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
Study: NCT04554667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Heavy Lifting Strength Training
Study: NCT05062382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary feeding intervention
Description: The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign.
Study: NCT01283360

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 1% Gel
Description: Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
Study: NCT00743340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
Study: NCT01929460

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: ciprofloxacin oral capsule (one capsule twice a day for 3 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for ciprofloxacin)
Description: oral placebo capsule (one capsule twice a day for 3 days)
Study: NCT00127660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=yes, value pricing=no

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=yes, value pricing = yes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Menu: calories=no, value pricing = no
Study: NCT03648541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution
Study: NCT02286752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: for reversal of neuromuscular block: sugammadex 2 mg kg-1
Study: NCT03867292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial
Description: The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
Study: NCT01083576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Description: topical application to CL lesions once daily for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin Alone Cream (15% paromomycin topical cream)
Description: topical application to CL lesions once daily for 20 days
Study: NCT02098759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epilepsy early diagnosis protocol
Description: Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epilepsy early diagnosis protocol
Description: Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
Study: NCT02823301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAMOS Program
Description: Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
Study: NCT02228629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CrocsRx Medical Silver cloud clogs
Study: NCT03888456

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: osteopathic treatment
Description: the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic treatment
Description: the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham
Description: the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
Study: NCT03429686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRT Intervention
Description: The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
Study: NCT01294631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg once daily and HCTZ 25 mg once daily
Description: Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35..
Study: NCT03125317

Intervention type: OTHER
Intervention: Music
Description: a kind of music which the participant likes will be listened using speakers

Intervention type: OTHER
Intervention: Valsalva maneuver
Description: Participant will be asked to take a deep breath and exhale the air out in 15 seconds

Intervention type: OTHER
Intervention: control
Description: No intervention
Study: NCT01561170

Intervention type: DEVICE
Intervention: Active Pulsed Electro-Magnetic Field (PEMF)
Description: One group of patients receive active devices. Both patients and investigator are blinded.

Intervention type: DEVICE
Intervention: Placebo Pulsed Electro-Magnetic Field (PEMF)
Description: One group of patients receive placebo devices. Both patients and investigator are blinded.
Study: NCT01864811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby-CIMT
Description: Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby-Massage
Description: For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
Study: NCT01276353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2020
Description: 10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
Study: NCT00438984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given IV or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT00442611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04973722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY06006
Description: 60 mg/1 ml, once every 6 months administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: 60 mg/1 ml, once every 6 months administered subcutaneously
Study: NCT00618865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Study: NCT04662645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Undergo embedded palliative care
Study: NCT00438984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03380013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
Study: NCT04256512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Elasto Gel Therapy Mittens and Foot Wraps
Study: NCT00438984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study: NCT01126450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Correlative studies
Study: NCT01743053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Care plus ReCell

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care